LEXINGTON, Mass., Nov 02, 2011 (BUSINESS WIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that new data on Feraheme® (ferumoxytol) Injection for intravenous (IV) use have been accepted for presentation at the American Society of Nephrology Kidney Week meeting taking place November 8-13, 2011 in Philadelphia, PA.
The Company and investigators will present the following data as posters:
- “The FIRST Head-to-head Comparison Study (Ferumoxytol Compared to Iron Sucrose Trial) of the Safety and Efficacy of Ferumoxytol with Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease” (Macdougal, et al.)
Poster Board LB-PO3156 – Saturday, Nov. 12, 2011, 9:30 a.m. – 2:30 p.m. - “The Safety of Feraheme® (Ferumoxytol) in Hemodialysis Patients at Three Dialysis Chains over a One Year Period” (Schiller, et al.)
Poster Board FR-PO1573 – Friday, Nov. 11, 2011, 9:30 a.m. – 2:30 p.m. - “The Effects of Feraheme® (Ferumoxytol) Administration on Target Hemoglobin Levels in Hemodialysis Patients across Three Dialysis Chains” (Sharma, et al.)
Poster Board FR-PO1603 – Friday, Nov. 11, 2011, 9:30 a.m. – 2:30 p.m.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. For additional company information, please visit https://www.amagpharma.com.
AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals:
Amy Sullivan, 617-498-3303
or
Carol Miceli, 617-498-3361
